Compare Stocks

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.23	$1.22	$0.59 ▼ $11.12	$87.24M	0.22	1.55 million shs	645,828 shs
IGXT IntelGenx Technologies	$0.17 +6.3%	$0.16	$0.09 ▼ $0.22	$29.69M	2.43	92,761 shs	73,325 shs
MACK Merrimack Pharmaceuticals	$14.68	$14.68	$11.53 ▼ $15.89	$213.30M	1.43	112,310 shs	113,575 shs
OPHT IVERIC bio		$1.30	$1.02 ▼ $4.50	$1.65B	1.49	159,109 shs	N/A
ORMP Oramed Pharmaceuticals	$2.20 -5.6%	$2.92	$1.67 ▼ $5.25	$89.14M	1.81	172,116 shs	240,759 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.82%	+6.03%	+6.96%	+4.24%	-86.73%
IGXT IntelGenx Technologies	-11.11%	-14.44%	-5.88%	+6.67%	-12.57%
MACK Merrimack Pharmaceuticals	0.00%	-0.27%	-0.27%	+11.63%	+16.42%
OPHT IVERIC bio	0.00%	0.00%	0.00%	0.00%	+38.19%
ORMP Oramed Pharmaceuticals	-2.92%	-12.41%	-17.08%	+6.39%	+2.64%

Start loving Mondays like this (Ad)

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	1.3795 of 5 stars	3.1	3.0	0.0	0.0	0.0	1.7	1.3
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPHT IVERIC bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	2.14	Hold	$22.25	1,708.94% Upside
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A
OPHT IVERIC bio	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ACRS, OPHT, MACK, IGXT, and ORMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
1/22/2024	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$31.25M	2.79	N/A	N/A	$2.22 per share	0.55
IGXT IntelGenx Technologies	$1.04M	28.55	N/A	N/A	($0.07) per share	-2.43
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
OPHT IVERIC bio	$209.98M	0.00	N/A	N/A	$3.00 per share	0.00
ORMP Oramed Pharmaceuticals	$1.34M	66.53	N/A	N/A	$4.04 per share	0.54

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.27	N/A	N/A	N/A	-283.15%	-64.56%	-49.10%	5/13/2024 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	-955.44%	N/A	-128.18%	N/A
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)
OPHT IVERIC bio	$63.09M	-$1.67	N/A	N/A	N/A	N/A	-141.53%	-41.88%	N/A
ORMP Oramed Pharmaceuticals	$5.53M	$0.14	15.71	∞	N/A	N/A	-7.15%	-5.70%	5/9/2024 (Estimated)

Latest ACRS, OPHT, MACK, IGXT, and ORMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/21/2024	Q4 2023	IGXT IntelGenx Technologies	N/A	-$0.02	-$0.02	-$0.03	N/A	$0.43 million
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
3/6/2024	Q4 2023	ORMP Oramed Pharmaceuticals	-$0.12	-$0.08	+$0.04	-$0.49	N/A	N/A
2/27/2024	Q4 2023	ACRS Aclaris Therapeutics	-$0.37	-$0.30	+$0.07	-$0.58	$3.96 million	$17.57 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPHT IVERIC bio	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	4.16	4.16
IGXT IntelGenx Technologies	N/A	0.41	0.40
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50
OPHT IVERIC bio	N/A	10.09	10.09
ORMP Oramed Pharmaceuticals	N/A	3.06	3.06

Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
IGXT IntelGenx Technologies	N/A
MACK Merrimack Pharmaceuticals	63.97%
OPHT IVERIC bio	45.39%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	5.50%
IGXT IntelGenx Technologies	42.05%
MACK Merrimack Pharmaceuticals	28.87%
OPHT IVERIC bio	3.00%
ORMP Oramed Pharmaceuticals	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	86	70.93 million	67.02 million	Optionable
IGXT IntelGenx Technologies	4	174.66 million	101.21 million	Not Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.34 million	Optionable
OPHT IVERIC bio	35	41.42 million	N/A	Optionable
ORMP Oramed Pharmaceuticals	12	40.52 million	35.66 million	Optionable

ACRS, OPHT, MACK, IGXT, and ORMP Headlines

Source	Headline
	Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Growth in Short Interest marketbeat.com - April 15 at 4:39 PM
	ORMP Apr 2024 2.500 put finance.yahoo.com - March 16 at 1:52 AM
	Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - March 9 at 2:05 PM
	Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop msn.com - February 21 at 6:04 PM
	Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders finanznachrichten.de - February 20 at 4:02 PM
	Oramed Letter to Shareholders prnewswire.com - February 20 at 8:30 AM
	ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform finance.yahoo.com - January 24 at 1:21 PM
	Oramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39 msn.com - November 28 at 8:11 PM
	Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 msn.com - November 2 at 10:07 AM
	Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago finance.yahoo.com - October 6 at 1:58 PM
	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company finance.yahoo.com - September 21 at 7:02 PM
	Other OTC Pharmaceuticals - Indonesia statista.com - September 19 at 1:52 PM
	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the ... bakersfield.com - September 15 at 10:14 AM
	Oramed and HTIT to form joint venture for oral drug products pharmaceutical-technology.com - August 3 at 7:38 AM
	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally finance.yahoo.com - August 2 at 11:08 AM
	Oramed Pharmaceuticals, Inc. jp.reuters.com - July 25 at 12:37 PM
	Taking a Closer Look At Oramed Pharmaceuticals Inc. (ORMP) Following Its Recent Trade knoxdaily.com - July 4 at 8:28 PM
	Investing in Oramed Pharmaceuticals Inc. (ORMP): What You Must Know knoxdaily.com - June 26 at 9:08 AM
	Oramed Pharmaceuticals Inc. (ORMP) may enjoy gains as insiders got busy in the recent days knoxdaily.com - June 20 at 3:22 PM
	Oramed to Present at the 83rd American Diabetes Association Conference finance.yahoo.com - June 20 at 10:21 AM
	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - June 17 at 2:50 PM
	ORMP’s short interest surges to 0.92 million shares knoxdaily.com - June 16 at 6:13 PM
	ORMP Stock Sees Surge of Approximately 0.25% in Last Five Days knoxdaily.com - June 8 at 8:08 AM
	ORMP: Advancing Development Efforts in China finance.yahoo.com - May 30 at 8:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aclaris Therapeutics

NASDAQ:ACRS

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

IntelGenx Technologies

OTCMKTS:IGXT

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

IVERIC bio

NASDAQ:OPHT

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Oramed Pharmaceuticals

NASDAQ:ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial